Industry aware of Medicare changes ahead

The new cost-based program leverages multiple available industry data sources, such as NADAC and PAC, to inform reimbursement, but a spokesperson would not be more specific.

Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.

Historically, RSV has been studied mainly in infants and older adults, but recent research shows that it also poses a significant threat to adults with asthma and COPD. However, research on the virus within these groups has been limited.

In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.

Optum Rx has eliminated reauthorization for almost 70 drugs for chronic diseases, about 10% of its overall pharmacy prior authorizations.

Research 'marries' traditional pathology with genomics.